This site is intended for US
Healthcare Professionals only

STAY INFORMED

This site is intended for US Healthcare Professionals only

Kura Oncology logo
STAY INFORMED

IT’S TIME TO CONSIDER

THE IMPACT OF THE

MENIN PATHWAY1-7

IT’S TIME TO CONSIDER THE

IMPACT OF THE

MENIN PATHWAY1-7

The menin pathway may play a critical role

The menin pathway may play a critical role in up to

in up to

50%

of
AMLs1-7

of AMLs1-7

Menin-dependent AML: a complex challenge

Among the complex circuitry of AML signaling systems, the menin pathway is thought to have a far-reaching impact on AML development and outcomes.1-7

The menin pathway is a crucial mediator in gene expression driving leukemogenesis1,2,4,8

Image of a circuit board representing the Menin Pathway
The menin pathway is a complex intracellular communication system that is most commonly activated by NPM1m or KMT2Ar. It is also associated with several other genetic alterations.1-4,8-11
When menin interacts with upstream genomic alterations, such as NPM1m and KMT2Ar, it drives downstream changes in gene expression, initiating leukemogenesis.1,2,8,12,13
Among cases of NPM1-m AML, 39% are co-mutated with FLT3-ITD and 25% are co-mutated with IDH1/2m.14,15
image of a circuit board representing menindependent mutations

By decoding the mechanisms through which menin affects leukemic cell behavior, it is possible to enhance the understanding of menin-dependent AMLs2,4

In NPM1-m AML, mOS typically declines following relapse16

In a study of patients with R/R NPM1-m AML, mOS was 7.8 months after the first treatment,
and 5.3 and 3.5 months after the second and third treatments16
Explore challenges
in NPM1-m AML
AML, acute myeloid leukemia; FLT3-ITD, FMS-like tyrosine kinase 3 receptor internal tandem duplication; IDH1/2m, isocitrate dehydrogenase 1 and 2 mutation; KMT2Ar, histone-lysine N-methyltransferase 2A rearrangement; mOS, median overall survival; NPM1-m, mutated nucleophosmin 1; NPM1m, nucleophosmin 1 mutation; R/R, relapsed or refractory.
References

References

1. Burrows F et al. Poster presented at: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications; October 26-30, 2017; Philadelphia, PA. 2. Candoni A et al. Hematol Rep. 2024;‌16(2):244-254. 3. Falini B et al. Blood Cancer Discov. 2024;5(1):8-20. 4. Issa GC et al. Leukemia. 2021;35(9):2482-2495. 5. Bertrums EJM et al. Haematologica. 2023;108(8):2044-2058. 6. National Cancer Institute. Accessed October 22, 2024. https://seer.cancer.gov/seertools/hemelymph/51f6cf59e3e27c3994bd547d/ 7. National Cancer Institute. Accessed October 22, 2024. https://seer.cancer.gov/seertools/hemelymph/5a7e288d1ef557f9c8636d31/ 8. Falini B et al. Blood. 2020;136(15):1707-1721. 9. Collins CT et al. Curr Opin Hematol. 2016;23(4):354-361. 10. Lu R et al. Cancer Cell. 2016;30(1):92-107. 11. Wang R et al. Front Oncol. 2022;12:972606. 12. Wang GG et al. Blood. 2005;106(1):254-264. 13. Choudhury R et al. EMBO Rep. 2011;‌12(5):463-469. 14. Papaemmanuil E et al. N Engl J Med. 2016;374(23):2209-2221. 15. Sharma N et al. Cancers (Basel). 2023;‌15(4):1177. 16. Issa GC et al. Blood Adv. 2023;7(6):933-942.

This site is intended for US
Healthcare Professionals only

STAY INFORMED
Kura Oncology logo